Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA.

According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales.

EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology's self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai Biotechnology's internal new drug discovery and antibody engineering capabilities. This enables Anmai Biotechnology to rapidly generate and screen a series of T cell junction molecules for specific diseases in the early detection stage, and push TCE candidate molecules that exhibit optimal efficacy and safety characteristics into the pre IND and clinical stages. EMB-06 is the third clinical trial project approved by Anmai Biotechnology (the first two being EMB-01 and EMB-02).

Anmai Biological Product Pipeline

Anmai Biotechnology is pleased to collaborate with Vignette on EMB-06, and Vignette Bio has excellent conditions to realize the potential of EMB-06, "said Dr. Wu Chenbing, CEO and founder of Anmai Biotechnology. EMB-06 is the first molecule developed using our independently developed T-cell junction platform, and has shown promising clinical efficacy in the evaluation of multiple myeloma patients. We look forward to further evaluating the potential of EMB-06 in autoimmune diseases.

The recent clinical data on the use of B cell clearance mechanisms in autoimmune diseases has demonstrated convincing results, "commented Michael Rome, Managing Director of Foresite Capital, Vignette's lead investor. EMB-06 is a promising clinical asset, and we look forward to establishing a leading company focused on developing T cell junction molecules for the treatment of autoimmune diseases.